Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
No risks detected for MEDP from our risk checks.
Medpace Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$213.02|
|52 Week High||US$105.48|
|52 Week Low||US$217.31|
|1 Month Change||7.47%|
|3 Month Change||21.94%|
|1 Year Change||94.75%|
|3 Year Change||345.18%|
|5 Year Change||632.28%|
|Change since IPO||659.70%|
Recent News & Updates
A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
Does the October share price for Medpace Holdings, Inc. ( NASDAQ:MEDP ) reflect what it's really worth? Today, we will...
Is Now An Opportune Moment To Examine Medpace Holdings, Inc. (NASDAQ:MEDP)?
Medpace Holdings, Inc. ( NASDAQ:MEDP ), might not be a large cap stock, but it saw a double-digit share price rise of...
|MEDP||US Life Sciences||US Market|
Return vs Industry: MEDP exceeded the US Life Sciences industry which returned 36.9% over the past year.
Return vs Market: MEDP exceeded the US Market which returned 33.4% over the past year.
Stable Share Price: MEDP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: MEDP's weekly volatility (4%) has been stable over the past year.
About the Company
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Medpace Holdings Fundamentals Summary
|MEDP fundamental statistics|
Is MEDP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MEDP income statement (TTM)|
|Cost of Revenue||US$413.59m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Oct 26, 2021
|Earnings per share (EPS)||5.10|
|Net Profit Margin||16.69%|
How did MEDP perform over the long term?See historical performance and comparison
Is Medpace Holdings undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MEDP ($213.02) is trading above our estimate of fair value ($201)
Significantly Below Fair Value: MEDP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MEDP is good value based on its PE Ratio (41.7x) compared to the US Life Sciences industry average (48.1x).
PE vs Market: MEDP is poor value based on its PE Ratio (41.7x) compared to the US market (18.3x).
Price to Earnings Growth Ratio
PEG Ratio: MEDP is poor value based on its PEG Ratio (3.5x)
Price to Book Ratio
PB vs Industry: MEDP is overvalued based on its PB Ratio (8.5x) compared to the US Life Sciences industry average (6.5x).
How is Medpace Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MEDP's forecast earnings growth (11.8% per year) is above the savings rate (2%).
Earnings vs Market: MEDP's earnings (11.8% per year) are forecast to grow slower than the US market (14.7% per year).
High Growth Earnings: MEDP's earnings are forecast to grow, but not significantly.
Revenue vs Market: MEDP's revenue (13.8% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: MEDP's revenue (13.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MEDP's Return on Equity is forecast to be high in 3 years time (20.7%)
How has Medpace Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MEDP has high quality earnings.
Growing Profit Margin: MEDP's current net profit margins (16.7%) are higher than last year (13.8%).
Past Earnings Growth Analysis
Earnings Trend: MEDP's earnings have grown significantly by 41.9% per year over the past 5 years.
Accelerating Growth: MEDP's earnings growth over the past year (47.2%) exceeds its 5-year average (41.9% per year).
Earnings vs Industry: MEDP earnings growth over the past year (47.2%) underperformed the Life Sciences industry 55.2%.
Return on Equity
High ROE: MEDP's Return on Equity (20.3%) is considered high.
How is Medpace Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: MEDP's short term assets ($641.2M) exceed its short term liabilities ($517.2M).
Long Term Liabilities: MEDP's short term assets ($641.2M) exceed its long term liabilities ($161.9M).
Debt to Equity History and Analysis
Debt Level: MEDP is debt free.
Reducing Debt: MEDP has no debt compared to 5 years ago when its debt to equity ratio was 25.1%.
Debt Coverage: MEDP has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MEDP has no debt, therefore coverage of interest payments is not a concern.
What is Medpace Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MEDP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MEDP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MEDP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MEDP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MEDP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
August Troendle (65 yo)
Dr. August James Troendle, M.D. has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1992 until August 01, 2021. Dr. Troendle foun...
CEO Compensation Analysis
Compensation vs Market: August's total compensation ($USD1.13M) is below average for companies of similar size in the US market ($USD6.29M).
Compensation vs Earnings: August's compensation has been consistent with company performance over the past year.
Experienced Management: MEDP's management team is considered experienced (2.8 years average tenure).
Experienced Board: MEDP's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Medpace Holdings, Inc.'s employee growth, exchange listings and data sources
- Name: Medpace Holdings, Inc.
- Ticker: MEDP
- Exchange: NasdaqGS
- Founded: 1992
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$7.616b
- Shares outstanding: 35.75m
- Website: https://www.medpace.com
Number of Employees
- Medpace Holdings, Inc.
- 5375 Medpace Way
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 22:42|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.